Agilon Health Inc Stock Price, News & Analysis

agilon health (NYSE: AGL) announced a significant leadership transition as CEO Steven Sell steps down from his roles as President, CEO, and Board Director. Ronald A. Williams, the company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman to lead the transition.

The Board has established an Office of the Chairman to manage interim operations and has initiated a search for a permanent CEO. The Office includes key executives such as the CFO, CMO, and other senior leaders. Additionally, the company has withdrawn its full year 2025 earnings guidance in conjunction with this leadership change.

Williams, a healthcare industry veteran and former Chairman and CEO of Aetna, will focus on driving operational improvements and supporting physician partners while the search for a new CEO is conducted.

agilon health (NYSE: AGL) has scheduled its second quarter 2025 financial results announcement for Tuesday, August 5, 2025, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results.

Participants can join the call by dialing (833) 470-1428 (U.S.) or +1 (404) 975-4839 (international) using code 938716. A simultaneous webcast will be available on the company's investor relations website, with an on-demand replay accessible after the call.

A new peer-reviewed study published in JAMA Health Forum reveals that senior patients under women physicians in agilon health's (NYSE: AGL) Value-Based Care model achieve equal or better clinical outcomes with reduced healthcare utilization compared to those under male physicians. The study analyzed nearly 900 primary care physicians (40% women) across 15 practice groups in seven states, examining data from 225,000 Medicare Advantage patients. Key findings show women physicians' patients had better diabetes management, fewer ER visits and hospitalizations, and higher composite Stars quality scores. Notably, the study found women physicians earned more per patient in the VBC model compared to male counterparts, effectively reversing the traditional gender pay gap. The research highlights how agilon's Total Care Model successfully transitions physicians from fee-for-service to value-based care, resulting in improved patient outcomes and healthier communities.

agilon health (NYSE: AGL) has released new research highlighting the effectiveness of their Value-Based Care (VBC) model in improving primary care access for Traditional Medicare patients. The study, published in Health Affairs Scholar, found that physicians who adopted agilon's VBC model saw 35% more new Traditional Medicare patients (8 additional patients per year) compared to those using fee-for-service models. VBC-adopting physicians also kept their practices open to new patients for nearly one additional month annually. The research analyzed data from 208 PCPs who adopted VBC and 3,657 who maintained fee-for-service models between 2019-2023. This study is particularly significant given the projected shortage of 57,000 primary care physicians by 2040 and the 29% decline in Medicare payments since 2001, which has led many physicians to limit Traditional Medicare patient intake.

agilon health (NYSE: AGL) announced its participation in Bernstein's 41st Annual Strategic Decisions Conference. The company will deliver a fireside chat presentation on Wednesday, May 28 at 4:30 PM Eastern Time. Investors can access the live webcast through agilon's investor relations website at investors.agilonhealth.com, with on-demand replays available shortly after the presentation.

agilon health (NYSE: AGL) reported its Q1 2025 financial results, showing a mixed performance with some declines but improved profitability. The company posted total revenues of $1.53 billion, down 4% from Q1 2024. Total platform members decreased to 605,000, including 491,000 Medicare Advantage members and 114,000 ACO REACH beneficiaries, reflecting previously disclosed market exits.

The company achieved net income of $12 million in Q1 2025, compared to a net loss of $6 million in Q1 2024. Medical margin was $128 million, down from $157 million, while Adjusted EBITDA decreased to $21 million from $29 million. The company maintains a strong capital position with $369 million in cash and equivalents and $35 million in total debt.

agilon health reaffirmed its full-year 2025 guidance, projecting total revenues between $5.85-6.025 billion and expects medical cost trends of 6.3% gross and 5.3% net for year 2+ markets.

agilon health (NYSE: AGL) has announced its participation in the upcoming BofA Securities 2025 Health Care Conference. The company will deliver a fireside chat presentation on Wednesday, May 14 at 1:00 PM Eastern Time.

Investors and interested parties can access the presentation through a simultaneous webcast available on the 'Events & Presentations' section of agilon health's investor relations website. On-demand replay options will be made available shortly after the presentation concludes.

agilon health (NYSE: AGL) has scheduled the release of its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results.

U.S. participants can join the call by dialing (833) 470-1428, while international participants can dial +1 (404) 975-4839, using participant code 095319. A simultaneous webcast will be available through the 'Events & Presentations' section of agilon's Investor Relations website. An on-demand replay will be accessible shortly after the call concludes.

agilon health (NYSE: AGL) reported its Q4 and full-year 2024 results, showing significant membership growth but facing financial challenges. Total revenue increased 44% to $1.52 billion in Q4 2024, while full-year revenue grew 40% to $6.06 billion.

Medicare Advantage membership rose 36% year-over-year to 527,000 members, with total platform members reaching 659,000. However, the company faced profitability challenges with a Q4 gross profit of negative $38 million and a net loss of $106 million.

For 2025, agilon expects approximately 20,000 new Medicare Advantage members from Class of 2025, while planning to exit partnerships affecting 54,000 members. The company projects continued elevated medical cost trends, with an estimated gross cost trend of 6.3% and 5.3% net for year 2+ markets.